DD297652A5 - Verfahren zur herstellung von polypeptiden, die als blocker von calcium-kanaelen verwendbar sind - Google Patents

Verfahren zur herstellung von polypeptiden, die als blocker von calcium-kanaelen verwendbar sind Download PDF

Info

Publication number: DD297652A5
Authority: DD; German Democratic Republic
Prior art keywords: cys; gly; lys; polypeptide; fraction
Prior art date: 1989-09-29

Application number

DD90343970A

Other languages

German (de)

English (en)

Inventor

Douglas Phillips

Nicholas A Saccomano

Robert A Volkmann

Original Assignee

��@��Kk��

��@��@��@��Kk��

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-09-29

Filing date

1990-09-12

Publication date

1992-01-16

1990-09-12 Application filed by ��@��Kk��, ��@��@��@��Kk�� filed Critical ��@��Kk��

1992-01-16 Publication of DD297652A5 publication Critical patent/DD297652A5/de

Links

108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 76
229920001184 polypeptide Polymers 0.000 title claims abstract description 74
102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 74
238000000034 method Methods 0.000 title claims description 25
108090000312 Calcium Channels Proteins 0.000 title abstract description 16
102000003922 Calcium Channels Human genes 0.000 title abstract description 16
125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 17
150000003839 salts Chemical class 0.000 claims abstract description 13
241000238898 Agelenopsis aperta Species 0.000 claims abstract description 9
239000002435 venom Substances 0.000 claims abstract description 8
231100000611 venom Toxicity 0.000 claims abstract description 8
210000001048 venom Anatomy 0.000 claims abstract description 8
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical group CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 39
DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 21
239000002245 particle Substances 0.000 claims description 12
239000003053 toxin Substances 0.000 claims description 12
231100000765 toxin Toxicity 0.000 claims description 12
239000011148 porous material Substances 0.000 claims description 11
239000002904 solvent Substances 0.000 claims description 10
238000001514 detection method Methods 0.000 claims description 5
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
230000008061 calcium-channel-blocking effect Effects 0.000 claims description 2
241000607479 Yersinia pestis Species 0.000 abstract description 6
239000000203 mixture Substances 0.000 abstract description 5
230000000903 blocking effect Effects 0.000 abstract description 4
201000010099 disease Diseases 0.000 abstract description 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 4
230000000694 effects Effects 0.000 abstract description 2
230000001404 mediated effect Effects 0.000 abstract description 2
210000004027 cell Anatomy 0.000 description 22
150000001875 compounds Chemical class 0.000 description 16
108700012359 toxins Proteins 0.000 description 11
238000004458 analytical method Methods 0.000 description 7
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 6
238000000746 purification Methods 0.000 description 6
239000000872 buffer Substances 0.000 description 5
YFHXZQPUBCBNIP-UHFFFAOYSA-N fura-2 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=3OC(=CC=3C=2)C=2OC(=CN=2)C(O)=O)N(CC(O)=O)CC(O)=O)=C1 YFHXZQPUBCBNIP-UHFFFAOYSA-N 0.000 description 5
229920004439 Aclar® Polymers 0.000 description 4
229940127291 Calcium channel antagonist Drugs 0.000 description 4
241000124008 Mammalia Species 0.000 description 4
150000001413 amino acids Chemical class 0.000 description 4
238000004587 chromatography analysis Methods 0.000 description 4
238000004108 freeze drying Methods 0.000 description 4
239000005023 polychlorotrifluoroethylene (PCTFE) polymer Substances 0.000 description 4
239000003643 water by type Substances 0.000 description 4
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
229910052786 argon Inorganic materials 0.000 description 3
229910052791 calcium Inorganic materials 0.000 description 3
239000011575 calcium Substances 0.000 description 3
238000001990 intravenous administration Methods 0.000 description 3
230000003387 muscular Effects 0.000 description 3
231100000614 poison Toxicity 0.000 description 3
239000002574 poison Substances 0.000 description 3
239000000243 solution Substances 0.000 description 3
238000006467 substitution reaction Methods 0.000 description 3
206010002383 Angina Pectoris Diseases 0.000 description 2
241000239290 Araneae Species 0.000 description 2
208000000289 Esophageal Achalasia Diseases 0.000 description 2
ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
206010020772 Hypertension Diseases 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
206010030136 Oesophageal achalasia Diseases 0.000 description 2
208000005107 Premature Birth Diseases 0.000 description 2
208000003782 Raynaud disease Diseases 0.000 description 2
208000012322 Raynaud phenomenon Diseases 0.000 description 2
108020004511 Recombinant DNA Proteins 0.000 description 2
206010042600 Supraventricular arrhythmias Diseases 0.000 description 2
241000251539 Vertebrata <Metazoa> Species 0.000 description 2
201000000621 achalasia Diseases 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
239000007900 aqueous suspension Substances 0.000 description 2
230000008901 benefit Effects 0.000 description 2
239000002775 capsule Substances 0.000 description 2
238000010367 cloning Methods 0.000 description 2
239000003480 eluent Substances 0.000 description 2
238000010828 elution Methods 0.000 description 2
238000005194 fractionation Methods 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
238000007918 intramuscular administration Methods 0.000 description 2
238000007912 intraperitoneal administration Methods 0.000 description 2
239000008101 lactose Substances 0.000 description 2
210000000663 muscle cell Anatomy 0.000 description 2
230000001537 neural effect Effects 0.000 description 2
210000002569 neuron Anatomy 0.000 description 2
239000008194 pharmaceutical composition Substances 0.000 description 2
239000002953 phosphate buffered saline Substances 0.000 description 2
230000035479 physiological effects, processes and functions Effects 0.000 description 2
-1 polyethylene Polymers 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
238000001243 protein synthesis Methods 0.000 description 2
238000012163 sequencing technique Methods 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
239000007790 solid phase Substances 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
238000012360 testing method Methods 0.000 description 2
WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 2
230000014616 translation Effects 0.000 description 2
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
KFDVPJUYSDEJTH-UHFFFAOYSA-N 4-ethenylpyridine Chemical compound C=CC1=CC=NC=C1 KFDVPJUYSDEJTH-UHFFFAOYSA-N 0.000 description 1
241000208140 Acer Species 0.000 description 1
NAPNAGZWHQHZLG-ZLUOBGJFSA-N Asp-Asp-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)N NAPNAGZWHQHZLG-ZLUOBGJFSA-N 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
208000031229 Cardiomyopathies Diseases 0.000 description 1
108091006146 Channels Proteins 0.000 description 1
108091026890 Coding region Proteins 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
ODDOYXKAHLKKQY-MMWGEVLESA-N Cys-Ile-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CS)N ODDOYXKAHLKKQY-MMWGEVLESA-N 0.000 description 1
UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
RVKIPWVMZANZLI-UHFFFAOYSA-N H-Lys-Trp-OH Natural products C1=CC=C2C(CC(NC(=O)C(N)CCCCN)C(O)=O)=CNC2=C1 RVKIPWVMZANZLI-UHFFFAOYSA-N 0.000 description 1
239000007995 HEPES buffer Substances 0.000 description 1
RVKIPWVMZANZLI-ZFWWWQNUSA-N Lys-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](N)CCCCN)C(O)=O)=CNC2=C1 RVKIPWVMZANZLI-ZFWWWQNUSA-N 0.000 description 1
CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
108010087066 N2-tryptophyllysine Proteins 0.000 description 1
238000005481 NMR spectroscopy Methods 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
206010036590 Premature baby Diseases 0.000 description 1
241000700159 Rattus Species 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
230000003187 abdominal effect Effects 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
239000007640 basal medium Substances 0.000 description 1
230000005540 biological transmission Effects 0.000 description 1
229940098773 bovine serum albumin Drugs 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
239000000480 calcium channel blocker Substances 0.000 description 1
235000013339 cereals Nutrition 0.000 description 1
210000000782 cerebellar granule cell Anatomy 0.000 description 1
210000001638 cerebellum Anatomy 0.000 description 1
239000013522 chelant Substances 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
239000000470 constituent Substances 0.000 description 1
238000011109 contamination Methods 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
238000012937 correction Methods 0.000 description 1
239000006184 cosolvent Substances 0.000 description 1
LEVWYRKDKASIDU-IMJSIDKUSA-N cystine group Chemical group C([C@@H](C(=O)O)N)SSC[C@@H](C(=O)O)N LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
229960000684 cytarabine Drugs 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
230000007613 environmental effect Effects 0.000 description 1
DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000019634 flavors Nutrition 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
210000000087 hemolymph Anatomy 0.000 description 1
238000009396 hybridization Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
PGHMRUGBZOYCAA-ADZNBVRBSA-N ionomycin Chemical compound O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/O)=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC(O)=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 PGHMRUGBZOYCAA-ADZNBVRBSA-N 0.000 description 1
PGHMRUGBZOYCAA-UHFFFAOYSA-N ionomycin Natural products O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 description 1
238000002955 isolation Methods 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
238000004949 mass spectrometry Methods 0.000 description 1
238000002156 mixing Methods 0.000 description 1
239000003068 molecular probe Substances 0.000 description 1
229930014626 natural product Natural products 0.000 description 1
239000002858 neurotransmitter agent Substances 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
239000012071 phase Substances 0.000 description 1
238000007747 plating Methods 0.000 description 1
229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
230000003518 presynaptic effect Effects 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
239000010453 quartz Substances 0.000 description 1
238000004366 reverse phase liquid chromatography Methods 0.000 description 1
239000000523 sample Substances 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008174 sterile solution Substances 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
239000011550 stock solution Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
- C07K14/43518—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from spiders
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/855—Proteins from animals other than mammals or birds
- Y10S530/858—Proteins from animals other than mammals or birds insects; venom

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Biophysics (AREA)
Insects & Arthropods (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Cardiology (AREA)
Biochemistry (AREA)
Gastroenterology & Hepatology (AREA)
Heart & Thoracic Surgery (AREA)
Zoology (AREA)
Toxicology (AREA)
Endocrinology (AREA)
Obesity (AREA)
Tropical Medicine & Parasitology (AREA)
Diabetes (AREA)
Hematology (AREA)
Epidemiology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Rheumatology (AREA)
Urology & Nephrology (AREA)
Reproductive Health (AREA)
Neurology (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

DD90343970A 1989-09-29 1990-09-12 Verfahren zur herstellung von polypeptiden, die als blocker von calcium-kanaelen verwendbar sind DD297652A5 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US07/415,139 US5122596A (en)	1989-09-29	1989-09-29	Polypeptides useful as blockers of calcium channels

Publications (1)

Publication Number	Publication Date
DD297652A5 true DD297652A5 (de)	1992-01-16

Family

ID=23644517

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DD90343970A DD297652A5 (de)	1989-09-29	1990-09-12	Verfahren zur herstellung von polypeptiden, die als blocker von calcium-kanaelen verwendbar sind

Country Status (27)

Country	Link
US (1)	US5122596A (no)
EP (1)	EP0425096B1 (no)
JP (1)	JPH0692440B2 (no)
KR (1)	KR930007435B1 (no)
CN (1)	CN1033976C (no)
AT (1)	ATE103611T1 (no)
AU (1)	AU626203B2 (no)
CA (1)	CA2026418C (no)
CZ (1)	CZ283651B6 (no)
DD (1)	DD297652A5 (no)
DE (1)	DE69007739T2 (no)
DK (1)	DK0425096T3 (no)
EG (1)	EG19316A (no)
ES (1)	ES2053118T3 (no)
FI (1)	FI96865C (no)
HU (1)	HU208705B (no)
IE (1)	IE64218B1 (no)
IL (1)	IL95765A (no)
MY (1)	MY106832A (no)
NO (1)	NO175208C (no)
NZ (1)	NZ235496A (no)
PH (1)	PH27403A (no)
PL (1)	PL164541B1 (no)
PT (1)	PT95424B (no)
RU (1)	RU2026866C1 (no)
YU (1)	YU184490A (no)
ZA (1)	ZA907782B (no)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4925664A (en) *	1986-10-20	1990-05-15	University Of Utah	Spider toxins and methods for their use as blockers of calcium channels and amino acid receptor function
US5677288A (en) *	1991-05-15	1997-10-14	Cypros Pharmaceutical Corporation	Use of aminoglycosides to protect against excitotoxic neuron damage
US5763568A (en) *	1992-01-31	1998-06-09	Zeneca Limited	Insecticidal toxins derived from funnel web (atrax or hadronyche) spiders
GB9208110D0 (en) *	1992-04-13	1992-05-27	Isis Innovation	Assay for antibodies that bind calcium channels
ATE157672T1 (de) *	1992-07-27	1997-09-15	Pfizer	Calcium-kanal blockierende polypeptide aus agelenopsis aperta
WO1994015960A1 (fr) *	1993-01-07	1994-07-21	Eisai Co., Ltd.	Peptide ayant des activites d'inhibition de liberation du glutamate et d'inhibition des canaux calciques
ES2075796B1 (es) *	1993-08-17	1996-03-01	Pfizer	Polipeptido de la agelenopsis aperta bloqueante de los canales de ca lcio
US5756462A (en) *	1994-01-19	1998-05-26	Pfizer Inc.	Pore forming peptides from Geolycosa riogrande
US5512592A (en) *	1994-09-09	1996-04-30	Wake Forest University	Method of producing cardiotonic effect and improving cardiac contractile function by administration of carnosine
US5776896A (en) *	1996-01-03	1998-07-07	Zeneca Limited	Analgesic peptides from venom of grammostola spatulata and use thereof
US5756663A (en) *	1996-01-03	1998-05-26	Zeneca Limited	Antiarrhythmic peptide from venom of spider Grammostola spatulata
US6063819A (en) *	1997-02-21	2000-05-16	Cypros Pharmaceutical Corp.	Neuroprotective poly-guanidino compounds which block presynaptic N and P/Q calcium channels
JP2006056805A (ja) *	2004-08-18	2006-03-02	Senmi Ekisu Co Ltd	カルシウムチャンネル阻害剤
US8299211B2 (en) *	2005-09-30	2012-10-30	The Board Of Trustees Of The University Of Illinois	Peptides and regulation of calcium channels

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4925664A (en) *	1986-10-20	1990-05-15	University Of Utah	Spider toxins and methods for their use as blockers of calcium channels and amino acid receptor function
US4950739A (en) *	1988-02-10	1990-08-21	New York University	Membrane calcium channels and factors and methods for blocking, isolating and purifying calcium channels
CA2006087C (en) *	1988-12-23	1999-09-21	Andrew G. Stapleton	Polypeptides isolated from the venom of the spider hololena curta
DD298412A5 (de) *	1989-04-28	1992-02-20	��@��Kk��	Verfahren zur herstellung von polypeptiden, die geeignet sind als antagonisten exzitatorischer aminosaeure-neurotransmitter und/oder blocker der calciumkanaele

1989
- 1989-09-29 US US07/415,139 patent/US5122596A/en not_active Expired - Lifetime
1990
- 1990-09-12 DD DD90343970A patent/DD297652A5/de not_active IP Right Cessation
- 1990-09-13 PH PH41197A patent/PH27403A/en unknown
- 1990-09-24 EP EP90310419A patent/EP0425096B1/en not_active Expired - Lifetime
- 1990-09-24 ES ES90310419T patent/ES2053118T3/es not_active Expired - Lifetime
- 1990-09-24 DE DE69007739T patent/DE69007739T2/de not_active Expired - Fee Related
- 1990-09-24 IL IL9576590A patent/IL95765A/en not_active IP Right Cessation
- 1990-09-24 DK DK90310419.8T patent/DK0425096T3/da active
- 1990-09-24 AT AT90310419T patent/ATE103611T1/de not_active IP Right Cessation
- 1990-09-26 PT PT95424A patent/PT95424B/pt not_active IP Right Cessation
- 1990-09-26 MY MYPI90001663A patent/MY106832A/en unknown
- 1990-09-27 CA CA002026418A patent/CA2026418C/en not_active Expired - Lifetime
- 1990-09-27 CZ CS904707A patent/CZ283651B6/cs not_active IP Right Cessation
- 1990-09-27 KR KR1019900015349A patent/KR930007435B1/ko not_active Expired - Fee Related
- 1990-09-27 EG EG57290A patent/EG19316A/xx active
- 1990-09-28 CN CN90108137A patent/CN1033976C/zh not_active Expired - Fee Related
- 1990-09-28 PL PL90287113A patent/PL164541B1/pl unknown
- 1990-09-28 NO NO904251A patent/NO175208C/no not_active IP Right Cessation
- 1990-09-28 IE IE349190A patent/IE64218B1/en not_active IP Right Cessation
- 1990-09-28 JP JP2260329A patent/JPH0692440B2/ja not_active Expired - Fee Related
- 1990-09-28 FI FI904789A patent/FI96865C/fi active IP Right Grant
- 1990-09-28 NZ NZ235496A patent/NZ235496A/en unknown
- 1990-09-28 YU YU184490A patent/YU184490A/sh unknown
- 1990-09-28 AU AU63660/90A patent/AU626203B2/en not_active Ceased
- 1990-09-28 ZA ZA907782A patent/ZA907782B/xx unknown
- 1990-09-28 RU SU904831267A patent/RU2026866C1/ru not_active IP Right Cessation
- 1990-09-28 HU HU906267A patent/HU208705B/hu not_active IP Right Cessation

Also Published As

Publication number	Publication date
CA2026418C (en)	1996-09-24
PL164541B1 (pl)	1994-08-31
CN1051182A (zh)	1991-05-08
HU906267D0 (en)	1991-03-28
PL287113A1 (en)	1991-09-09
DE69007739T2 (de)	1994-07-07
FI96865C (fi)	1996-09-10
EP0425096B1 (en)	1994-03-30
NO175208B (no)	1994-06-06
JPH0692440B2 (ja)	1994-11-16
IE64218B1 (en)	1995-07-26
EP0425096A1 (en)	1991-05-02
NZ235496A (en)	1991-12-23
US5122596A (en)	1992-06-16
IL95765A (en)	1995-07-31
IL95765A0 (en)	1991-06-30
KR930007435B1 (ko)	1993-08-10
NO904251D0 (no)	1990-09-28
NO904251L (no)	1991-04-02
MY106832A (en)	1995-07-31
PT95424B (pt)	1998-06-30
DK0425096T3 (da)	1994-05-02
AU6366090A (en)	1991-04-11
YU184490A (sh)	1993-05-28
CZ283651B6 (cs)	1998-05-13
EG19316A (en)	1994-12-30
RU2026866C1 (ru)	1995-01-20
FI904789A0 (fi)	1990-09-28
CA2026418A1 (en)	1991-03-30
HU208705B (en)	1993-12-28
NO175208C (no)	1994-09-14
AU626203B2 (en)	1992-07-23
KR910006326A (ko)	1991-04-29
DE69007739D1 (de)	1994-05-05
ATE103611T1 (de)	1994-04-15
ZA907782B (en)	1992-05-27
PT95424A (pt)	1991-05-22
IE903491A1 (en)	1991-04-10
CN1033976C (zh)	1997-02-05
PH27403A (en)	1993-06-21
CZ470790A3 (cs)	1998-02-18
JPH03120299A (ja)	1991-05-22
FI96865B (fi)	1996-05-31
ES2053118T3 (es)	1994-07-16
HUT55036A (en)	1991-04-29

Legal Events

Date	Code	Title	Description
2001-04-12	ENJ	Ceased due to non-payment of renewal fee

Publication	Publication Date	Title
DD298412A5 (de)	1992-02-20	Verfahren zur herstellung von polypeptiden, die geeignet sind als antagonisten exzitatorischer aminosaeure-neurotransmitter und/oder blocker der calciumkanaele
DE69313650T2 (de)	1998-01-08	Calcium-kanal blockierende polypeptide aus agelenopsis aperta
DE69007739T2 (de)	1994-07-07	Polypeptide verwertbar als Kalziumkanälen-Blocker.
DE19725619A1 (de)	1998-12-24	Peptide als Agonisten und/oder Inhibitoren der Amyloidbildung und Zytotoxizität sowie der Verwendung bei Alzheimer'schen Krankheit, beim Typ II Diabetes mellitus und bei spongiformen Encephalopathien
WO2006042745A2 (de)	2006-04-27	Chemisch modifizierte iapp - peptidanaloga
DE60112424T2 (de)	2006-05-24	Protonen-abhängiges na+-kanal hemmendes polypeptid
DE69312320T2 (de)	1997-10-30	Den kalzium kanal blokierende polypeptide aus filistata hibernalis.
DE69318567T2 (de)	1998-09-10	Kalzium-kanal-blockierende polypeptide aus theraphosidae aphonopelma
EP1023445B1 (de)	2005-08-17	Cadherin derived growth factor und seine verwendung
DE69813232T2 (de)	2003-11-13	Wespe pompilid neuropeptide
JP3503978B2 (ja)	2004-03-08	グルタミン酸遊離阻害活性及びカルシウムチャネル阻害活性を有するペプチド